- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 24, Issue 41, 2018
Current Pharmaceutical Design - Volume 24, Issue 41, 2018
Volume 24, Issue 41, 2018
-
-
Pharmacological Adjuncts to Vitrectomy Surgery
Authors: Maria C. Savastano, Alfonso Savastano and Stanislao RizzoPharmacological adjuncts to vitrectomy surgery are useful tools to better deal with surgery. Their introduction has enriched the therapeutic choice before, during and after operations. Although several classifications could be made to frame adjuncts to vitrectomy, we preferred to divide the pharmacological adjuncts to vitrectomy surgery for therapeutic use in the pre-operatory procedure (neo-adjuvant), for intraoperative us Read More
-
-
-
Pharmacotherapy of Myopic Choroidal Neovascularization
Authors: Hacer Isildak, Stephen G. Schwartz and Harry W. FlynnBackground: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients. Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial grow Read More
-
-
-
Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration
Authors: Elad Moisseiev and Anat LoewensteinExudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. Read More
-
-
-
Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments
Authors: Pierluigi Iacono, Lisa Toto, Eliana Costanzo, Monica Varano and Maria C. ParravanoBackground: Central serous chorioretinopathy (CSC) is the fourth most frequent retinal disorder in terms of prevalence. It typically occurs in young subjects and affects men more often than women. CSC is characterized by serous retinal detachment (SRD) involving mainly the macular area. The clinical course is usually selflimited, with spontaneous resolution within 3 months. The persistence of SRD or multiple relapse may result i Read More
-
-
-
Pharmacotherapy of Vitreomacular Traction
Authors: Ran Wan, Thomas Hong, Yasser Tariq and Andrew ChangVitreomacular traction occurs due to incomplete or anomalous posterior vitreous detachment. Over time, the vitreous pulls anteriorly and causes retinal distortion and eventually reduced vision. Traditionally, vitreomacular traction was treated with vitrectomy surgery. In the past few years, there is a paradigm shift towards pharmacologic vitreolysis, which involves the intravitreal injection of enzymatic and non-enzymatic ag Read More
-
-
-
Pharmacotherapy for Choroidal Neovascularization Due to Uncommon Causes
Authors: Christine P.S. Ho and Timothy Y.Y. LaiBackground: Choroidal neovascularization (CNV) in adults is most commonly associated with neovascular age-related macular degeneration (AMD) and pathologic myopia. Though less common, CNV can also develop from other conditions such as uveitis, central serous chorioretinopathy, angioid streaks, intraocular tumors, hereditary chorioretinal dystrophies, or can be idiopathic in origin. If left untreated, CNV may cause visual lo Read More
-
-
-
The Role of Steroids and NSAIDs in Prevention and Treatment of Postsurgical Cystoid Macular Edema
Authors: Andrzej Grzybowski and Piotr KanclerzBackground: Pseudophakic cystoid macular edema (PCME) remains one of the most common visionthreatening complication of phacoemulsification cataract surgery (PCS). Pharmacological therapy is the current mainstay of both prophylaxis, and treatment of PCME in patients undergoing PCS. We aimed to review pharmacological treatment options for PCME, which primarily include topical steroids, topi Read More
-
-
-
Current and Future Pharmacologic Therapies for Diabetic Retinopathy
Authors: Victor M. Villegas and Stephen G. SchwartzBackground: Currently, diabetic retinopathy is the leading cause of permanent visual loss in workingage adults in industrialized nations. The chronic microangiopathic changes associated with diabetic retinopathy lead to the most common causes of severe permanent visual loss: diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Multiple studies have evaluated different pharmacotherapies for different lev Read More
-
-
-
Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy
Authors: Peifu Jiao, Qiaohong Geng, Peng Jin, Gaoxing Su, Houyun Teng, Jinlong Dong and Bing YanBlockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. Nevertheless, therapeutic antibodies also exhibit several disadvantages such as low tumor penetration, difficulty in crossing physiological barriers, lacking oral bioavailability, high Read More
-
-
-
Dietary Approaches to Attain Fish Health with Special Reference to their Immune System
Authors: Thea Magrone, Matteo A. Russo and Emilio JirilloFish despite their low collocation in the vertebrate phylum possess a complete immune system. In teleost fish both innate and adaptive immune responses have been described with melanomacrophage centers (MMCs) equivalent to mammalian germinal centers. Primary lymphoid organs are represented by the thymus and kidney, while spleen and mucosa-associated lymphoid tissues act as secondary lymphoid organs. Functi Read More
-
-
-
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Authors: Huanbo Tan, Wencheng Su, Wenyu Zhang, Pengju Wang, Michael Sattler and Peijian ZouPeptides and proteins are two classes of molecules with attractive possibilities for therapeutic applications. However, the bottleneck for the therapeutic application of many peptides and proteins is their short halflives in vivo, typically just a few minutes to hours. Half-life extension strategies have been extensively studied and many of them have been proven to be effective in the generation of long-acting therapeuti Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
